|
| Status |
Public on May 01, 2019 |
| Title |
Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [RNA-seq] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Drug-tolerant “persister” cells underlie the emergence of drug-resistant clones and allow residual tumors to survive therapy; thus, represent an attractive therapeutic target to mitigate relapse. With the promising outcome, yet some resistance cases surfaced after the approval of venetoclax (ABT-199), we defined a novel invasive drug resistance mechanism induced by Bcl2 inhibitor via examining the evolution of drug tolerant persister clones generated with ABT-199 treatment. The ABT-199 drug-tolerant persister cells showed genetic alteration by losing the copy number at 18q21 paralleled with BCL2, PMAIP1 and TCF4 gene downregulation. The persister status are generated through major enhancer-remodeling mediated transcriptional activation of the super enhancer, which offered unique opportunity for overcoming the drug resistance. The insight of major determinant for ABT-199 persistence evolution identified the molecular vulnerability in Bcl2 inhibitor resistant lymphoma cells through CDK7 pathway inhibition. The combined CDK7 and BCL2 inhibition was found to be more effective against ABT-199 persistence ex vivo and in vivo rather than the parental line, and CDK7 inhibition eliminated the persister phenotype by blocking dynamic active enhancer formation to further prevent the evolution of drug resistance. Together, these studies unified genetic alteration and non-mutational adaptive response as a drug resistance mechanism, more importantly, demonstrated a rationale for transcriptional inhibition-based combination strategies to prevent and overcome drug resistance in B-cell malignancies.
|
| |
|
| Overall design |
All samples were prepared in biological triplicates. 1x106 Cells were treated for 6 hours with either 50/250nm THZ1 or DMSO at equal concentration as vehicle control. Total RNA was isolated using the Rneasy Plus Mini (Qiagen Cat# 74134) and ERCC spike in controls (Life Technologies, Cat 4456740) were added after total RNA extraction (1ul to 5000ng RNA). Library prep was conducted using TruSeq Stranded mRNA Library Prep Kit (Illumina Cat #RS-122-2101/2) according to manufacture instruction. RNA sequencing was done on HiSeq 2500v4 high output (50-bp, single-end reads).
|
| |
|
| Contributor(s) |
Park PM, Qi J |
| Citation(s) |
31085176 |
| |
| Submission date |
Jun 21, 2018 |
| Last update date |
Jul 31, 2019 |
| Contact name |
Jun Qi |
| Organization name |
Dana-Farber
|
| Department |
Cancer Biology
|
| Lab |
Qi
|
| Street address |
450 Brookline Avenue
|
| City |
Boston |
| State/province |
Massachusetts |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (35)
|
|
| This SubSeries is part of SuperSeries: |
| GSE116132 |
Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas |
|
| Relations |
| BioProject |
PRJNA477352 |
| SRA |
SRP151047 |
Less...
More...